J.P. Morgan Maintains Their Buy Rating on Incyte Corp (INCY)

By Carrie Williams

In a report issued on May 12, Cory Kasimov from J.P. Morgan maintained a Buy rating on Incyte Corp (INCYResearch Report), with a price target of $90. The company’s shares closed yesterday at $76.11.

According to TipRanks.com, Kasimov is a 2-star analyst with an average return of 0.2% and a 40.4% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., BioMarin Pharmaceutical Inc., and ACADIA Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Incyte Corp with a $87 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $88.83 and a one-year low of $57. Currently, Incyte Corp has an average volume of 1.32M.

Based on the recent corporate insider activity of 87 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INCY in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A.